Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Todd Smith

Vascular Surgery Tyler, TX Medical Doctor

NPI 1215902598 CMS profile 9352

619 S Fleishel Ave, Ste 203, Tyler, TX 75701

Open in the dashboard

General payments

$10,055

245 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Todd Smith of Tyler, TX is reported in the CMS Open Payments database as having received $10,055 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,444 30
2024 General $1,578 21
2023 General $1,930 49
2022 General $1,782 36
2021 General $1,308 41
2020 General $1,471 42
2019 General $541 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Smith
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Todd Smith were reported at $1,444. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Todd Smith Vascular Surgery median Middle half National median
2019 $541 $796 $226–$2,363 $163
2020 $1,471 $348 $118–$1,110 $114
2021 $1,308 $471 $158–$1,421 $132
2022 $1,782 $725 $222–$2,183 $149
2023 $1,930 $836 $257–$2,440 $160
2024 $1,578 $909 $252–$2,619 $164
2025 $1,444 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,719 106 payments
  2. Boston Scientific Corporation $1,394 49 payments
  3. Inari Medical, Inc. $823 14 payments
  4. Shockwave Medical, Inc $773 18 payments
  5. Silk Road Medical, Inc. $634 4 payments
  6. Bard Peripheral Vascular, Inc. $587 14 payments
  7. Cardiovascular Systems Inc. $368 12 payments
  8. Neuros Medical, Inc. $355 4 payments
  9. CryoLife, Inc. $343 4 payments
  10. Abbott Laboratories $284 5 payments
  11. Other $773 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,962 243 payments
  2. Travel and Lodging $93 2 payments
Products named General payments · program years 2019–2025
  1. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,059 34 payments
  2. CT THROMBECTOMY SYSTEM KIT $823 14 payments
  3. FLOWTRIEVER CATHETER, S $823 14 payments
  4. ENROUTE Transcarotid Stent $521 3 payments
  5. ENROUTE Transcarotid Neuroprotection System $521 3 payments
  6. GORE EXCLUDER Iliac Branch Endoprosthesis $483 9 payments
  7. EXCLUDER Iliac Branch Endoprosthesis $469 13 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $387 5 payments
  9. Altius $355 4 payments
  10. GORE TAG Conformable Thoracic Stent Graft $354 4 payments
  11. Other $6,455 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

460

Median for Vascular Surgery: 122

Drug cost

$25,867

Median for Vascular Surgery: $14,135

Branded share of claims

81.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 19 $15,061
Eliquis Apixaban Brand 11 $6,205
Clopidogrel Clopidogrel Bisulfate Brand 214 $1,474
Prasugrel Hcl Generic 15 $1,174
Cilostazol Generic 44 $715
Acetaminophen-Codeine Acetaminophen With Codeine Brand 72 $518
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 57 $396
Gabapentin Generic 28 $323

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$182,159

Medicare's payments for the services billed

Medicare patients

608

Average age 75

Services billed

1,793

266 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 62%
Arthritis 55%
Diabetes 47%
Chronic kidney disease 45%
COPD 38%
Heart failure 34%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record